Sat.Sep 21, 2024 - Fri.Sep 27, 2024

article thumbnail

For Pharmacists With Substance Use Disorders, Recovery Is Possible

Drug Topics

Pharmacy professionals are at an increased risk of substance abuse due to many factors, but long-term recovery can be achieved with the help of specialized recovery networks.

154
154
article thumbnail

STAT+: Pfizer pulls sickle cell treatment Oxbryta off global markets

STAT

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.  The decision is a stunning blow for a drug that was approved in 2019 , heralded as a new way to treat the inherited blood disorder. Pfizer acquired the maker of Oxbryta, a biotech company called Global Blood Therapeutics, in 2022 for $5.4 billion.

144
144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Approves Dupilumab as Add-On Maintenance Therapy For Adults With COPD

Pharmacy Times

Dupilumab is the first biologic medicine for patients with chronic obstructive pulmonary disease to be approved in the US.

FDA 145
article thumbnail

Morehouse School of Medicine launches pain equity course focused on racial healthcare disparities

Fierce Healthcare

One of the first pain equity courses for medical students is launching at the Morehouse School of Medicine this fall. | The course offers insights into fostering safe, trustworthy, transparent and empathetic patient-provider interactions. It also emphasizes how to address the unique preferences and needs of Black patients in pain.

144
144
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Schizophrenia Drug Approved by FDA Represents First New Treatment Option in Decades

Drug Topics

The approval of xanomeline and trospium chloride (Cobenfy) from Bristol Myers Squibb represents a “transformative moment in the treatment of schizophrenia.

FDA 211
article thumbnail

Four more health care workers reported illnesses after caring for bird flu case in Missouri

STAT

An investigation into the still unexplained human H5N1 bird flu infection in Missouri has turned up four additional health care workers who developed mild respiratory illness symptoms after caring for the patient in hospital in August, the Centers for Disease Control and Prevention reported on Friday. It is not clear if any of these people were actually infected with H5N1; they were not tested at the time when they were ill.

Hospitals 145

More Trending

article thumbnail

Startup Particle Health files antitrust lawsuit against Epic alleging it uses monopoly power to block competition

Fierce Healthcare

What began as a dispute between two health tech companies over healthcare data exchange practices has now led to a federal lawsuit alleging antitrust violations. | Venture-backed health tech company Particle Health filed an antitrust lawsuit against Epic in the Southern District of New York alleging that the electronic health records giant is trying to muscle out competition in the payer platform market.

145
145
article thumbnail

Q&A: How Cebranopadol Could Help Address Gaps in Pain Management

Drug Topics

Albert Dahan, MD, PhD, discusses how cebranopadol could fit into the broader landscape of pain management therapies.

201
201
article thumbnail

Opinion: Sequencing wastewater material may be the key to getting a grip on the H5N1 bird flu outbreak

STAT

Despite no known infections of H5N1 bird flu among its dairy cows, Missouri recently detected a case in a person with no apparent exposure to possibly infected animals or related products (i.e., raw milk). A close contact and two health workers who cared for the person all developed respiratory symptoms , but were never tested. There has not yet been a wider uptick of other potential cases in the same community to indicate efficient human-to-human transmission — the evolution of which is

145
145
article thumbnail

Study Finds Ruxolitinib May Slow Fibrosis Progression in Myelofibrosis

Pharmacy Times

Researchers found that PF4/Cxcl4, a key driver of fibrosis, was up regulated on all proteomes.

145
145
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Healthcare conferences to put on your calendar for 2024-2025

Fierce Healthcare

Looking for healthcare events in the fall of 2024 and 2025? We rounded up some of the top conferences, both virtual and live, that are on the calendar. | Here's our roundup of some of the top events in healthcare scheduled in the fall of 2024 and 2025.

135
135
article thumbnail

Weekend ICYMI: September 16 to September 20

Drug Topics

In case you missed it, this week we had news about end-of-year PBM reform on the horizons, cebranopadol as a transformational new pain therapy, success in co-administration of RSV and shingles vaccines, and more.

Vaccines 187
article thumbnail

STAT+: What Pfizer’s decision to pull its sickle cell drug means for patients, the company, and the FDA

STAT

Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and scrambling for ways to notify their patients about a drug that has long divided the community.  The move underscored the severity of the risks recently seen in studies of the drug, Oxbryta , in which researchers have reported a number of deaths among patients who were receiving it.

FDA 145
article thumbnail

Although AI Tools Are Advancing, Expert Says There Is a Need for More Tools Post-Diagnosis in Myeloma

Pharmacy Times

Although Madabhushi said there are emerging tools for clinical decision support, he said there is a greater need for tools further downstream in the post-diagnosis stages.

142
142
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Pfizer issues global market withdrawal of sickle cell disease therapy Oxbryta

Fierce Pharma

Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago. | Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to its $5.4 billion acquisition of Global Blood Therapeutics two years ago.

136
136
article thumbnail

Now Trending: Fall Vaccine Hesitancy, AI in Respiratory Care

Drug Topics

Check out this recap of articles published on our sister sites during the past week.

Vaccines 187
article thumbnail

STAT+: FDA approves schizophrenia drug that could alter how disorder is treated

STAT

For decades, doctors caring for people with schizophrenia have relied on mood-regulating drugs that target the brain chemical dopamine. On Thursday, the Food and Drug Administration approved for the first time a new type of medicine that may change the way the psychiatric disorder is treated.  The drug, called Cobenfy, will be sold by Bristol Myers Squibb.

FDA 145
article thumbnail

FDA Approves Osimertinib for Unresectable EGFR-Mutated Lung Cancer

Pharmacy Times

The decision is based on positive results from the phase 3 LAURA trial.

FDA 138
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Pomelo Care acquires the Doula Network to offer hybrid maternity care model

Fierce Healthcare

Pomelo Care, a value-based virtual provider of maternity care, has acquired the Doula Network, now offering virtual and in-person maternity care. | The acquisition expands the company’s reach to more than 15 million covered lives, including more than 1 in 6 Medicaid beneficiaries nationally.

132
132
article thumbnail

Immunization Roundup: FDA Approves FluMist, Updated Novavax COVID-19 Vaccine

Drug Topics

Catch up on important immunization news from the month of September.

article thumbnail

Opinion: Millions of people are missing from U.S. disability data

STAT

Many disabled people are not included in official U.S. data. This is because there is “ No Box to Check ” to indicate their particular disability on surveys from the U.S. Census Bureau and other federal agencies. The questions used to identify people with disabilities are missing millions. Two question sets are most often used to assess disability in U.S. federal surveys: the American Community Survey Six (ACS-6) or the Washington Group Short Set (WG-SS).

145
145
article thumbnail

Women With Prior Knowledge of COVID-19 Vaccine More Likely Receive Vaccination While Pregnant

Pharmacy Times

Investigators reported that more than half of individuals had great knowledge about protecting themselves from COVID-19.

Vaccines 139
article thumbnail

J.D. Power: Consumer experience with telehealth a mixed bag

Fierce Healthcare

While consumers give telehealth high marks for convenience, overall experience is fairly mixed, according to a new report. | While consumers give telehealth high marks for convenience, overall experience is fairly mixed, according to a new report.

131
131
article thumbnail

Chronic Pain Linked to Higher Anxiety, Depression in Youth

Drug Topics

Study findings raise concern about increased pain and disability, poorer pain self-management, and impaired quality of life during adolescence that can continue into young adulthood.

149
149
article thumbnail

Can MRIs ensure prostate cancer screening does more good than harm?

STAT

Prostate cancer presents a tricky screening challenge. Catching it early could mean dodging a painful journey with advanced cancer. Yet a sizable majority of prostate cancers are “indolent” — slow growing tumors that most likely would never metastasize during the patient’s lifetime, and whose treatment  would do more harm than good.

145
145
article thumbnail

FDA Grants Bimekizumab-Bkzx Approval for Treatment of Chronic Immune-Mediated Inflammatory Diseases

Pharmacy Times

Approved with 3 new indications, bimekizumab-bkzx is the first and only interleukin-17 inhibitor approved for these diseases.

article thumbnail

HHS OIG finds gaps in opioid treatment for Medicare, Medicaid enrollees

Fierce Healthcare

Many counties do not have medication for opioid use disorder (MOUD) services available through providers and treatment programs, and even in counties that do, Medicare and Medicaid beneficiaries of | A new report from HHS OIG looked at access to medication for opioid use disorder services and found many high need counties do not have specialized providers.

129
129
article thumbnail

Lupus Nephritis Treatment Shows Positive Results in Phase 3 Trial

Drug Topics

Genentech said it’s sharing the data with global health authorities to make the therapy available to patients as soon as possible.

149
149
article thumbnail

Sickle cell community scrambles to find safe plan after a drug is pulled from the market

STAT

She knew what it was to have pain she couldn’t put into words, but this was worse. As a child, Nana-Bilkisu Habib had felt it in her arms or legs or back, but this was everywhere, as if her whole body were shutting down. She couldn’t move. Her dad had to carry her into the car and lay her in the backseat. She spent the drive to the hospital reciting verses of the Quran, praying that she would make it through.

Insurance 144
article thumbnail

Favorable Outcomes Possible With IVIG Treatment for Multisystem Inflammatory Syndrome in Children

Pharmacy Times

Further trials are required to examine the long-term feasibility of intravenous immunoglobulin (IVIG) for multisystem inflammatory syndrome.

139
139
article thumbnail

HHS watchdog flags potential remote monitoring fraud. Stakeholders say concerns about misuse are overblown

Fierce Healthcare

HHS OIG released an analysis of recent RPM claims data, flagging evidence of gaps in CMS oversight. Stakeholders say the report is hyperbolic.

130
130
article thumbnail

Getting Involved as a Pre-Pharmacy Student 

Pharmacy Is Right For Me

Hi Future Pharmacists! My name is Tazche Turner and I am a fourth year PharmD Candidate at the University of North Carolina’s (UNC) Eshelman School of Pharmacy. My passions for science, business and service led me to pursue a career in pharmacy. Throughout pharmacy school, I immersed myself into numerous organizations and leadership positions to really explore all pharmacy has to offer, but the organization I found my pharmacy home in was the Student National Pharmaceutical Association (SNPhA).

article thumbnail

STAT+: Electronic health records giant Epic Systems sued over alleged monopolistic practices

STAT

The health data company Particle Health has filed an antitrust lawsuit against Epic Systems, alleging that the electronic health record vendor has used its control of patient data to thwart competition and undermine its business. The suit filed Monday in federal court in the Southern District of New York is a full-throated assault on Epic’s dominance in the market for electronic health records, charging that the privately held company has become a “behemoth” and a “mo

145
145